Categories: AddictionNews

Ibogaine by David Dardashti Optimizes Algorithm for Fentanyl Treatment

Innovative Treatment Protocol Aims to Revolutionize Fentanyl Treatment

MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) — For those struggling with fentanyl addiction, Ibogaine by David Dardashti is revolutionizing the way the deadly opiate is treated.

Fentanyl Treatment

Ibogaine by David Dardashti has developed an optimized algorithm for fentanyl treatment that takes into account the individual’s prior use of the drug and any associated potency. This algorithm also accounts for any other drugs that the individual may be consuming, addressing drug interactions with opiates in a proactive manner. “By utilizing implicit differentiation, our algorithm is tailored specifically to the needs of each patient,” said David Dardashti. “This method allows us to adjust the algorithm based on the observations of previous operations, while taking into consideration the other substances the patient may be taking.” The algorithm adds additional days of treatment for those who are currently taking or who have recently taken fentanyl in combination with other opiates.

The algorithm has been designed to account for any potential future opiate use, and any associated potency, by using the same core components but adjusting one variable at a time. This innovative method is being used to drastically reduce the accessibility of and dependence on fentanyl, and to minimize the physical and psychological side effects associated with the highly potent drug. Ibogaine by David Dardashti hopes that this breakthrough algorithm will revolutionize drug treatment around the world.

For more information on Ibogaine by David Dardashti and their optimized algorithm for fentanyl treatment, please visit their website at www.ibogaineclinic.com.

CONTACT: Gavriel Dardashti
+17869301880
gavriel@ibogaineclinic.com

Staff

Recent Posts

NervGen Pharma Announces Proposed Amendment to Warrants

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB:…

2 hours ago

MyndTec Inc. Completes Ninth Tranche of Non-Brokered Private Placement

Mississauga, Ontario--(Newsfile Corp. - December 12, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"),…

4 hours ago

Dominari Holdings Announces Change of Record Date and Payment Date for $10 Million Cash Dividend

NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) is pleased to announce…

4 hours ago

ISHI Health Launches Virtual Heart Failure Clinics in California and Arizona

SAN DIEGO, Dec. 12, 2025 /PRNewswire/ -- ISHI Health, an innovator in AI-enabled virtual cardiac…

4 hours ago

Zealthy Review 2026: How Zealthy Compares to FitRx and RoenRx for Weight Loss & GLP-1 Care

LOS ANGELES, CA / ACCESS Newswire / December 12, 2025 / The landscape of weight…

4 hours ago

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

ESTERO, FL / ACCESS Newswire / December 12, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP)…

4 hours ago